CTLA4 and neoplasm: The core hypothesis is that PD-1/CTLA-4 dual blockade can enhance tumor antigen-specific T cell responses and inhibit regulatory T cell (Tregs) function, synergizing with the immunomodulatory effects of AG chemotherapy to overcome PDAC treatment resistance (25–27).